European Dividend aristocrat and Danish pharmaceutical company Novo Nordisk AS (NOVO-B.CO) reported on Wednesday a revenue growth of 9.0% and 4.8% earnings-per-share growth in Q4. Net profit in Q4 rose to 8.72 billion DKK ($1.29 billion) from DKK8.5 billion a year earlier. Sales in Q4 rose to DKK32.42 billion against analysts’ expectations of DKK31.95 billion.
For the 2020 outlook, sales growth is expected to be 3-6%, and operating profit growth is expected to be 1-5%.
The company proposed a final dividend of DKK5.35 a share for 2019, bringing the total dividend to DKK8.35. This means a dividend of DKK0.20, given the previous total dividend of DKK8.15.
Source: Novo Nordisk IR news
